Published ahead of print on November 2, 2006, doi:10.1164/rccm.200608-1109OC
Am. J. Respir. Crit. Care Med., Volume 175, Number 3, February 2007, 282-287
A more recent version of this article appeared on February 1, 2007
Submitted on August 8, 2006
Accepted on November 2, 2006
Latent Tuberculosis Infection Treatment and T-cell responses to M. tuberculosis-Specific Antigens
Cynthia BE Chee1*, Kyi W KhinMar2, Suay H Gan1, Timothy MS Barkham3, Mariappan Pushparani1, and Yee T Wang1
1 Singapore Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore, Singapore,
2 Department of Clinical Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore,
3 Department of Pathology and Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore
* To whom correspondence should be addressed. E-mail: cynthia_chee{at}ttsh.com.sg.
Rationale: There is currently no available test for monitoring the effect of treatment of latent tuberculosis infection (LTBI) to indicate cure or predict risk of subsequent progression to disease.
Objective: We used the T-SPOT.TB assay, which measures T-cell interferon-gamma (IFN ) responses to Mycobacterium tuberculosis-specific peptides early secretory antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10), to determine the effect of LTBI treatment on these responses.
Methods: 226 TB contacts with positive T-SPOT.TB results underwent repeat testing upon LTBI treatment completion. The majority (96%) received six months of isoniazid. The pre- and post-treatment T-SPOT.TB results were analyzed according to the combined and separate responses to ESAT-6 and CFP-10 antigens.
Results: The T-SPOT.TB reverted to negative in 85 (37.6%) contacts at treatment completion. Treatment had a significant effect on the response to CFP-10 (p<0.001; reversion rate 48.6%), but not on the response to ESAT-6 (p=0.081, reversion rate 21.6%). The median spot-forming cells (SFCs) / 2.5X105 peripheral blood mononuclear cells (PBMCs) pre and post treatment was 6 vs 4.5 for ESAT-6 (p=0.116) and 11 vs 4 for CFP-10 (p<0.001). There was a significant difference between the median falls with CFP-10 (6 SFCs / 2.5X105 PBMCs) and ESAT-6 (zero SFCs / 2.5X105 PBMCs) (p<0.001). Significantly different age-related T-cell responses to the two antigens were found.
Conclusion: LTBI treatment had a differential effect on the T-cell responses to ESAT-6 and CFP-10 as measured by the T-SPOT.TB. The quantitative response to CFP-10 may be a useful LTBI treatment monitoring tool.
Key words: T-SPOT.TB, ESAT-6, CFP-10, interferon gamma responses, isoniazid
This article has been cited by other articles:
|
|
|
|
 
A C Hesseling, A M Mandalakas, H L Kirchner, N N Chegou, B J Marais, K Stanley, X Zhu, G Black, N Beyers, and G Walzl
Highly discordant T cell responses in individuals with recent exposure to household tuberculosis
Thorax,
October 1, 2009;
64(10):
840 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Richeldi
Diagnosing Latent Tuberculosis Infection: Guess Who's Coming to Dinner?
Am. J. Respir. Crit. Care Med.,
July 1, 2009;
180(1):
1 - 2.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Mack, G. B. Migliori, M. Sester, H. L. Rieder, S. Ehlers, D. Goletti, A. Bossink, K. Magdorf, C. Holscher, B. Kampmann, et al.
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
Eur. Respir. J.,
May 1, 2009;
33(5):
956 - 973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Diel, R. Loddenkemper, K. Meywald-Walter, R. Gottschalk, and A. Nienhaus
Comparative Performance of Tuberculin Skin Test, QuantiFERON-TB-Gold In Tube Assay, and T-Spot.TB Test in Contact Investigations for Tuberculosis
Chest,
April 1, 2009;
135(4):
1010 - 1018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kobashi, K. Mouri, S. Yagi, Y. Obase, N. Miyashita, N. Okimoto, T. Matsushima, T. Kageoka, and M. Oka
Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis
Chest,
May 1, 2008;
133(5):
1196 - 1202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. Yew and C. C. Leung
Update in Tuberculosis 2007
Am. J. Respir. Crit. Care Med.,
March 1, 2008;
177(5):
479 - 485.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Beamer, D. K. Flaherty, B. Vesosky, and J. Turner
Peripheral Blood Gamma Interferon Release Assays Predict Lung Responses and Mycobacterium tuberculosis Disease Outcome in Mice
Clin. Vaccine Immunol.,
March 1, 2008;
15(3):
474 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hussain, N. Talat, F. Shahid, and G. Dawood
Longitudinal Tracking of Cytokines after Acute Exposure to Tuberculosis: Association of Distinct Cytokine Patterns with Protection and Disease Development
Clin. Vaccine Immunol.,
December 1, 2007;
14(12):
1578 - 1586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. P. J. Franken, B. F. P. J. Koster, A. W. J. Bossink, S. F. T. Thijsen, J. J. M. Bouwman, J. T. van Dissel, and S. M. Arend
Follow-Up Study of Tuberculosis-Exposed Supermarket Customers with Negative Tuberculin Skin Test Results in Association with Positive Gamma Interferon Release Assay Results
Clin. Vaccine Immunol.,
September 1, 2007;
14(9):
1239 - 1241.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lalvani
Diagnosing Tuberculosis Infection in the 21st Century: New Tools To Tackle an Old Enemy
Chest,
June 1, 2007;
131(6):
1898 - 1906.
[Abstract]
[Full Text]
[PDF]
|
|
|
Copyright © 2006 American Thoracic Society
|
|
|
